- Bristol Myers Squibb launches Kopozgo® (Mavacamten) in India for treatment of symptomatic Obstructive Hypertrophic Cardiomyopathy BioSpectrum India
- BMS launches selective cardiac myosin inhibitor drug in India The Hindu
- Bristol Myers Squibb launches heart med Mavacamten in India ET Pharma
- Bristol Myers Squibb Launches Kopozgo in India as First Oral Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy geneonline.com
- Bristol Myers Squibb launches Kopozgo (Mavacamten) in India for obstructive hypertrophic cardiomyopathy Express Pharma
Bristol Myers Squibb launches Kopozgo® (Mavacamten) in India for treatment of symptomatic Obstructive Hypertrophic Cardiomyopathy BioSpectrum IndiaBMS launches selective cardiac myosin inhibitor drug in India The HinduBristol Myers Squibb launches heart med Mavacamten in India ET PharmaBristol Myers Squibb Launches Kopozgo in India as First Oral Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy geneonline.comBristol Myers Squibb launches Kopozgo (Mavacamten) in India for obstructive hypertrophic cardiomyopathy Express Pharma by Soban News (international And National News)
